Freeze-dried fruit sold at Sam's Club recalled over listeria risk
Doehler Dry Ingredient Solutions, LLC issued the recall for Member's Mark Freeze Dried Fruit Variety Pack 15-count boxes due to the potential contamination of the organism that can "cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems," the FDA notice says.
As of Thursday, July 31, the date the recall was published, no illnesses have been reported due to the possible contamination.
The freeze-dried fruit was shipped to distribution centers in Alabama, Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Iowa, Idaho, Illinois, Indiana, Kansas, Louisiana, Maryland, Maine, Michigan, Minnesota, Missouri, Mississippi, Montana, North Carolina, North Dakota, Nebraska, New Hampshire, New Jersey, New Mexico, Nevada, New York, Ohio, Oklahoma, Pennsylvania, Puerto Rico, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, Wisconsin, West Virginia and Wyoming.
How was the possible listeria found?
According to the notice, the Cartersville, Georgia-based company discovered the possible listeria via internal testing of its products.
The recalled freeze-dried fruit was distributed between July 1 and July 25 and sold in Sam's Club retail locations. The products were packaged in foil pouches inside a corrugated box, which had the lot number and expiration date located on the bottom, according to the notice.
What freeze-dried fruit products were recalled?
The recalled products are all 15-count Member's Mark Freeze-Dried Fruit Variety Packs with the UPC 1 93968 50900 2 and use-by dates ranging from June 24, 2027, to July 25, 2027, according to the notice.
What are symptoms of listeria infection?
According to the Centers for Disease Control and Prevention (CDC), symptoms of listeria infection include:
Fever
Flu-like symptoms, such as muscle aches and fatigue
Headache
Stiff neck
Confusion
Loss of balance
Seizures
The FDA warns that while healthy individuals may suffer only short-term symptoms, such as high fever, severe headache, stiffness, nausea, abdominal pain and diarrhea, a listeria infection can cause miscarriages and stillbirths among pregnant women.
What should consumers do if they have the recalled freeze-dried fruit?
Consumers who have the recalled freeze-dried fruit in their possession should not consume the product, according to the FDA, adding that they "should discard it and may visit any Sam's Club for a full refund."
Anyone with questions can contact Doehler Dry Ingredient Solutions, LLC's Customer Service at 770-387-0451 from Monday to Friday, 8 a.m. to 5 p.m. EST.
This article originally appeared on USA TODAY: Freeze-dried fruit sold at Sam's Club recalled
Solve the daily Crossword
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
I'm almost 50, but I look 10 years younger. My secret weapon? This anti-aging eye cream that's on sale for $19
Shoppers say it "reduced hyperpigmentation" and works "way better than expensive eye creams." When I turned 40, with a baby on the way, it became much more challenging to conceal the puffy eyes and dark circles of a sleepless night. A few years later, I added another kiddo, and tired eyes became my trademark look. I tried dozens of products to revive the delicate under-eye area, but it wasn't until CeraVe's Eye Repair Cream that I actually started to notice long-term improvements. As someone with easily irritated eyes, this lightweight cream is my daily go-to. So, when my four-year-old is up at 3 a.m. with an ear infection, CeraVe's eye cream will help to hide the evidence of a sleepless night. I'm not the only one who loves this affordable beauty product — according to our data, hundreds of Yahoo readers have also snapped it up. Read on to find out why I'm obsessed — and to shop it on sale for $19. The details This fragrance-free, ophthalmologist-tested eye cream contains three essential ceramides and hydrating hyaluronic acid. It's made with a patented delivery system that continually releases the ingredients so your eyes stay moisturized all day long. With continued regular use, you will notice a reduction in dark circles and under-eye puffiness. Apply a few dots of the cream to your under-eye area in the morning and evening, and gently smooth until fully absorbed. It works great alone or under makeup. The CeraVe eye cream, developed with dermatologists, is non-comedogenic and great for all skin types. What I like about it It's great for sensitive eyes: I love how the CeraVe cream moisturizes without irritating my sensitive eyes. It absorbs quickly and is a great primer for my under-eye concealer. Each application requires just a few dots of the product, so the little tube goes a long way. Dermatologist-approved: I also appreciate that the product has been recognized by the Canadian Dermatology Association and has been well-tested by experts. It's not just some gimmicky eye cream but one that has a lot of science behind it, which matters to me. Great for hyperpigmentation: With more than 3,600 reviews and a 4.3-star rating, it's clear I am not the only one who swears by this hydrating cream. One shopper said they wished they had found it sooner as it significantly "reduced hyperpigmentation" under their eyes. They stated that their under-eye area became 30 per cent lighter, which they say is a "big win." Not greasy: Another reviewer mentions how "non-greasy" the cream is and that it doesn't irritate sensitive eyes, while another person calls it a "wonderful product." $19 $24 at Amazon Other mature beauty & fashion recommendations: I'm a 48-year-old mom who loves shopping at Amazon — 12 summer tops I'm buying, all under $50 I tried on 13 Reitmans dresses on sale for under $75 — if you're in your 40s or 50s, these styles are seriously good These viral Amazon eye masks help make my bags look 'less puffy' — and they're on sale right now Room for improvement It's not a quick-fix eye cream: This product is great, but it's not a fast-acting wonder cream. You need to use it for several weeks, if not months, to see any remarkable improvements. Also, you can't skip applications, or it will set your results back. Commit to using it for a solid six months before you assess if it's working for you. Some Amazon reviewers mentioned they saw no visible difference after a few weeks; however, from personal experience, the cream takes time to do its thing. I promise, if you stick with it, your under-eye area will improve — just don't give up! It's not as hydrating as other eye creams: The eye cream could be a tad thicker; however, it probably wouldn't absorb as well if it was. CeraVe has a unique formula that may take a while to work, but once it does, it's great. My advice? Don't throw in the towel just yet. What reviewers are saying With hundreds of five-star reviews, I am far from the only fan of CeraVe's Eye Repair Cream. One reviewer, who has struggled with "hollow eyes" and "hyperpigmentation" their "whole life," says the eye cream has made their under-eye area "about 30 per cent lighter" — a "big win" for them. They write that their dark eye bags are "barely noticeable" after applying makeup. "I will definitely be buying [it] again." Another shopper agrees it's a "great cream for dark circles," adding that it works "way better than expensive eye creams." "Every dollar spent on it is worth it," they write. "My advice," echoes a third shopper: "Throw out all your expensive skin care" and only buy CeraVe products. They're "reasonably priced," and, importantly, "they work." Despite thousands of five-star reviews, some warn it's "not a miracle product" and agree it can take a few months to show noticeable results. The verdict I love CeraVe products, and this one is no exception. It's gentle on my eye area, and after using it for a few months straight, I saw significant improvements in my dark circles and under-eye puffiness. That said, if you are looking for something to quickly erase a night out with the girls or a long overseas flight, this is probably not going to provide the quick fix you need. This lightweight cream will yield results, but it's going to take some time. If you commit to using it twice a day for the next six months, I'm certain you will be impressed with what you see (and don't see) under your eyes in the morning.
Yahoo
an hour ago
- Yahoo
Oscar Health (OSCR) Q2 Earnings: What To Expect
Health insurance company Oscar Health (NYSE:OSCR) will be reporting earnings this Wednesday morning. Here's what to expect. Oscar Health beat analysts' revenue expectations by 6.9% last quarter, reporting revenues of $3.05 billion, up 42.1% year on year. It was a stunning quarter for the company, with a solid beat of analysts' EPS estimates. Is Oscar Health a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Oscar Health's revenue to grow 33.7% year on year to $2.97 billion, slowing from the 46% increase it recorded in the same quarter last year. Adjusted loss is expected to come in at -$0.84 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Oscar Health has missed Wall Street's revenue estimates four times over the last two years. Looking at Oscar Health's peers in the health insurance providers segment, some have already reported their Q2 results, giving us a hint as to what we can expect. CVS Health delivered year-on-year revenue growth of 8.4%, beating analysts' expectations by 5.1%, and Alignment Healthcare reported revenues up 49%, topping estimates by 5.7%. CVS Health's stock price was unchanged after the resultswhile Alignment Healthcare was up 5.7%. Read our full analysis of CVS Health's results here and Alignment Healthcare's results here. The euphoria surrounding Trump's November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the health insurance providers stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.3% on average over the last month. Oscar Health is down 17% during the same time and is heading into earnings with an average analyst price target of $11.29 (compared to the current share price of $13.95). When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we've found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
GoodRx (GDRX) To Report Earnings Tomorrow: Here Is What To Expect
Healthcare tech company GoodRx (NASDAQ:GDRX) will be reporting earnings this Wednesday after the bell. Here's what to expect. GoodRx met analysts' revenue expectations last quarter, reporting revenues of $203 million, up 2.6% year on year. It was a slower quarter for the company, with a significant miss of analysts' EPS estimates and a significant miss of analysts' customer base estimates. It lost -200,000 customers and ended up with a total of 6.4 million. Is GoodRx a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting GoodRx's revenue to grow 2.5% year on year to $205.7 million, slowing from the 5.8% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.10 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. GoodRx has missed Wall Street's revenue estimates twice over the last two years. Looking at GoodRx's peers in the healthcare technology segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Hims & Hers Health delivered year-on-year revenue growth of 72.6%, missing analysts' expectations by 1.1%, and Omnicell reported revenues up 5%, topping estimates by 4.9%. Omnicell's stock price was unchanged following the results. Read our full analysis of Hims & Hers Health's results here and Omnicell's results here. Debates around the economy's health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the healthcare technology stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.3% on average over the last month. GoodRx is down 4.6% during the same time and is heading into earnings with an average analyst price target of $6.32 (compared to the current share price of $4.52). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
